Spinogenix Announces Launch of a Phase 2 Clinical Trial Evaluating ...
WEB5 days ago · Phase 2 trial is designed to evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophreniaLOS ANGELES, Sept. 25, 2024 (GLOBE ...
Spinogenix Announces Launch of a Phase 2 Clinical Trial
WEB5 days ago · Spinogenix has initiated a randomized, double-blind, placebo-controlled multicenter Phase 2 study to assess the efficacy, safety, and tolerability of SPG302 administered once-daily as an oral ...
Spinogenix Announces FDA Clearance of IND Application for SPG302…
WEBMay 29, 2024 · Spinogenix Announces FDA Clearance of IND Application for SPG302, a Novel Therapy for the Treatment of ALS. SPG302 is being developed as a once-a-day pill with the potential to regenerate synapses to reverse declines in cognitive and motor function in people with ALS.
Spinogenix Announces Open Enrollment for Phase 2 Study …
WEBAug 1, 2024 · The Phase 2 trial will evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of a once-a day pill of SPG302 in adult participants with mild-to-moderate Alzheimer’s disease.
Spinogenix Announces FDA Clearance of IND Application for SPG302…
WEBMay 29, 2024 · SPG302 is being developed as a once-a-day pill with the potential to regenerate synapses to reverse declines in cognitive and motor function in people with ALS.
Spinogenix Awarded $3 Million NIH Grant to Support Continued ...
WEBSep 12, 2023 · Spinogenix is advancing SPG302 as the first synaptic regenerative therapy in Alzheimer’s disease. NIH previously awarded Spinogenix a phase one grant (number 1R43AG058278) for its research and development of this unique treatment for …
FDA Clears Phase 1/2 Clinical Trial for Spinogenix’s ALS Treatment SPG302
WEBJun 17, 2024 · SPG302 aims to treat ALS by regenerating synapses, potentially reversing declines in cognitive, respiratory, and motor functions. The FDA has granted orphan drug designation to SPG302, providing benefits like exemption from user fees and tax credits for clinical research.
Spinogenix Announces Launch of a Phase 2 Clinical Trial
WEB5 days ago · SPG302 has completed the Phase 1 safety study in healthy subjects in Australia and has U.S. FDA IND clearance for evaluation of ALS. SPG302 also received HREC approval for a Phase 2 trial in Alzheimer’s disease. Additional information on the ALS trial (NCT05882695) and Alzheimer’s disease trial (NCT06427668) may be found on ClinicalTrials.gov.
Spinogenix Announces Open Enrollment for Phase 2 Study …
WEBAug 1, 2024 · SPG302 is a once-a-day pill being developed as a regenerative treatment for neurodegenerative and neuropsychiatric diseases with the unique ability to restore synapses, the key connections...
FDA OKs Phase 1/2 clinical trial of small molecule SPG302 in ALS
WEBJun 5, 2024 · Spinogenix will soon launch a Phase 1/2 clinical trial in the U.S. to test its investigational small molecule SPG302 in people with amyotrophic lateral sclerosis (ALS).